Hayley Virgil


Final FDA blueprint available for MFS end point in nonmetastatic CRPC trials

August 13, 2021

The FDA has officially released its finalized recommendation for the use of metastases-free survival as an end point in clinical trials evaluating treatments for patients with nonmetastatic castration-resistant prostate cancer.

Study highlights gender and racial disparities in receiving optimal treatment for kidney cancer

July 21, 2021

“To our knowledge, this study represents the first attempt to assess the associations between demographic factors and receipt of non–guideline-based treatment among patients with kidney cancer,” the authors of the study wrote.